Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years

Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 ye...

Full description

Saved in:
Bibliographic Details
Published in:Liver research 2020-12, Vol.4 (4), p.206-211
Main Authors: Tsuchiya, Kyohei, Ohki, Takamasa, Sato, Koki, Kondo, Mayuko, Toda, Nobuo, Tagawa, Kazumi
Format: Article
Language:English
Subjects:
Elderly patients
Hepatocellular carcinoma (HCC)
Locoregional therapy
Propensity score matching
Radiofrequency ablation (RFA)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 years. A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled. They were categorized into the ≥80-year-old group and the control group (aged
ISSN:2542-5684
2542-5684
DOI:10.1016/j.livres.2020.11.005